View source for Recommendation for Duration of DAPT in Patients With ACS Treated With CABG

==2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease<ref name="pmid27751237">{{cite journal| author=Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA et al.| title=2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=J Thorac Cardiovasc Surg | year= 2016 | volume= 152 | issue= 5 | pages= 1243-1275 | pmid=27751237 | doi=10.1016/j.jtcvs.2016.07.044 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27751237  }} </ref>==

==Duration of DAPT in Patients With ACS Treated With CABG:Recommendation==
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of
DAPT therapy after ACS (''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])''<nowiki>"</nowiki>
|}